Ranbaxy Labs brings record breaking CB

Fierce competition for mandate results in deal having to be sold below par.
IndiaÆs Ranbaxy Laboratories has raised $440 million, including a $40 million greenshoe, from an aggressively priced five-year convertible bond that will be used for potential future acquisitions and capex.

The five-year deal, which was jointly arranged by Citigroup, Deutsche Bank, Morgan Stanley and UBS, is the second largest CB out of India after HDFCÆs $500 million bond last year and the largest ever from an Indian pharma company.

Ranbaxy is IndiaÆs largest pharmaceutical company and ranks among the top 10 producers of generic medicines worldwide, according to its Web site.

The zero-coupon bond was launched after the Indian stock market closed on Wednesday February 15 and initially proved a tough sell. Typically, over...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222